Read by QxMD icon Read

Venlafaxine Weight Gain

Adeline Abbe, Bruno Falissard
BACKGROUND: Internet is a particularly dynamic way to quickly capture the perceptions of a population in real time. Complementary to traditional face-to-face communication, online social networks help patients to improve self-esteem and self-help. OBJECTIVE: The aim of this study was to use text mining on material from an online forum exploring patients' concerns about treatment (antidepressants and anxiolytics). METHODS: Concerns about treatment were collected from discussion titles in patients' online community related to antidepressants and anxiolytics...
October 23, 2017: JMIR Mental Health
Adam Wichniak, Aleksandra Wierzbicka, Małgorzata Walęcka, Wojciech Jernajczyk
PURPOSE OF REVIEW: The aim of this review article was to summarize recent publications on effects of antidepressants on sleep and to show that these effects not only depend on the kind of antidepressant drugs but are also related to the dose, the time of drug administration, and the duration of the treatment. RECENT FINDINGS: Complaints of disrupted sleep are very common in patients suffering from depression, and they are listed among diagnostic criteria for this disorder...
August 9, 2017: Current Psychiatry Reports
David S Baldwin, Lambros Chrones, Ioana Florea, Rebecca Nielsen, George G Nomikos, William Palo, Elin Reines
The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on the nature, incidence and severity of treatment-emergent adverse events (TEAEs) during acute (6/8) week treatment in 11 randomized, double-blind placebo-controlled short-term studies in major depressive disorder: six with an active reference. Symptoms following discontinuation were assessed through the Discontinuation-Emergent Signs and Symptoms checklist in three studies. Long-term (⩽52 weeks) tolerability was evaluated in five open-label extension studies...
March 2016: Journal of Psychopharmacology
Faruk Uguz, Mine Sahingoz, Buket Gungor, Fadime Aksoy, Rustem Askin
OBJECTIVE: The aim of the present study was to examine weight gain and its association with clinical and sociodemographic characteristics in patients using newer antidepressants. METHODS: The study had a cross-sectional design. A total of 362 consecutive psychiatric patients taking antidepressant drugs for 6 to 36 months were included in the study. RESULTS: The prevalence rate of weight gain was 55.2%; 40.6% of the patients had a weight gain of 7% or more compared to the baseline...
January 2015: General Hospital Psychiatry
Paul L Nguyen, Shabbir M H Alibhai, Shehzad Basaria, Anthony V D'Amico, Philip W Kantoff, Nancy L Keating, David F Penson, Derek J Rosario, Bertrand Tombal, Matthew R Smith
CONTEXT: Androgen-deprivation therapy (ADT) is a key component of treatment for aggressive and advanced prostate cancer, but it has also been associated with adverse effects on bone, metabolic, cardiovascular, sexual, and cognitive health as well as body composition. OBJECTIVE: To review the current literature on the adverse effects of ADT and strategies for ameliorating harm from ADT. EVIDENCE ACQUISITION: The Medline database (through PubMed) was searched from inception to August 1, 2013, for studies documenting the side effects of ADT and for randomized and prospective trials of interventions to mitigate those side effects...
May 2015: European Urology
David S Baldwin
Many patients with depression require long-term treatment to provide optimal clinical outcomes. Long-term tolerability is therefore important in facilitating adherence to treatment and thereby maintaining control over depressive symptoms. While the newer selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs) are generally better tolerated than older treatments, such as tricyclic antidepressants and monoamine oxidase inhibitors, they can still cause nausea, headache, sleep disturbances, dry mouth, weight gain and sexual dysfunction...
2006: International Journal of Psychiatry in Clinical Practice
Sarah R Blumenthal, Victor M Castro, Caitlin C Clements, Hannah R Rosenfield, Shawn N Murphy, Maurizio Fava, Jeffrey B Weilburg, Jane L Erb, Susanne E Churchill, Isaac S Kohane, Jordan W Smoller, Roy H Perlis
IMPORTANCE: Short-term studies suggest antidepressants are associated with modest weight gain but little is known about longer-term effects and differences between individual medications in general clinical populations. OBJECTIVE: To estimate weight gain associated with specific antidepressants over the 12 months following initial prescription in a large and diverse clinical population. DESIGN, SETTING, AND PARTICIPANTS: We identified 22,610 adult patients who began receiving a medication of interest with available weight data in a large New England health care system, including 2 academic medical centers and affiliated outpatient primary and specialty care clinics...
August 2014: JAMA Psychiatry
Georgios Paslakis, Sabine Westphal, Bettina Hamann, Maria Gilles, Florian Lederbogen, Michael Deuschle
INTRODUCTION: The neuropeptide ghrelin stimulates hunger and weight gain. Ghrelin actions have been associated with depression in a number of preclinical and clinical studies, although some studies comparing basal peripheral ghrelin levels between depressed patients and controls found no differences between the groups. METHODS: Twenty patients with a melancholic depressive episode and 15 controls received a 75 g glucose load and ghrelin levels were measured at 0, 30, 60 and 90 min after the beginning of the test...
June 2014: Journal of Psychopharmacology
Faruk Uguz
Edema is a rarely observed adverse effect of the usage of antidepressant, with only few case reports of peripheral edema in the literature. This report included 2 patients who presented with rapid weight gain related to edema after the use of venlafaxine and paroxetine alone. The adverse effects developed within 2 to 3 weeks after the start of the treatments and completely resolved after their discontinuation.
January 2014: Clinical Neuropharmacology
Pierre M Bet, Jacqueline G Hugtenburg, Brenda W J H Penninx, Witte J G Hoogendijk
Side effects of antidepressants are usually underreported in clinical trials and large scale naturalistic studies are restricted to six months of use. We examined the prevalence and nature of patient-perceived side effects and their determinants during long-term antidepressant use in a naturalistic setting. Subjects, aged 19 to 67 years, in the Netherlands Study of Depression and Anxiety were recruited from primary care and specialized mental health care covered 927 cases of single antidepressant use. In 64% of cases, on average, 2...
November 2013: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
Charles T Nguyen, Jennifer A Rosen, Robert G Bota
OBJECTIVE: 5-HT2C receptor antagonists are thought to contribute toward increased appetite and obesity. Aripiprazole acts as a partial agonist at the 5-HT2C receptor; hence, it is thought to cause little or no significant weight gain when used alone. We theorize that, in the presence of antidepressants with high serotonergic activity, aripiprazole acts as an antagonist at the 5-HT2C receptor, thus increasing the potential for weight gain. Conversely, in environments with low serotonergic activity, aripiprazole acts as an agonist at the 5-HT2C receptor, therefore having less potential for weight gain...
2012: Primary Care Companion to CNS Disorders
Claudia Schilling, Maria Gilles, Werner F Blum, Emmerich Daseking, Michael Colla, Bettina Weber-Hamann, Florian Lederbogen, Bertram Krumm, Isabella Heuser, Stefan A Wudy, Daniel Kopf, Michael Deuschle
Treatment with several psychopharmacological agents has been associated with increased leptin plasma concentrations. We measured leptin plasma concentrations in 76 adult depressed patients after a 6-day washout phase and again after 35 days of treatment with amitriptyline or paroxetine, as well as in 73 depressed patients after 28 days of treatment with either mirtazapine or venlafaxine. Leptin plasma concentrations increased during treatment with amitriptyline and mirtazapine, even after controlling for increased body mass index and irrespective of response to treatment [14...
February 2013: Journal of Clinical Psychopharmacology
Michal Dubovický, Eszter Császárová, Zuzana Brnoliaková, Eduard Ujházy, Jana Navarová, Mojmír Mach
About 3% of pregnant women are treated with antidepressant drugs during gestation. After delivery the number of treated women increases to 5 to 7%. Most prescribed antidepressants in pregnancy are selective serotonin re-uptake inhibitors and/or serotonin and noradrenaline re-uptake inhibitors, such as fluoxetine, paroxetine, sertraline, citalopram and venlafaxine (VENF). Despite the fact that VENF has been assigned to pregnancy category C by the FDA, experimental studies with this drug are rare. The aim of this pilot study was to investigate the effect of prenatal administration of VENF on early postnatal development of rat offspring and selected biochemical variables at weaning of pups...
June 2012: Interdisciplinary Toxicology
Xiao-Jie Liu, Yu-Zhi Zhou, Zhong-Feng Li, Jie Cui, Zhen-Yu Li, Xiao-Xia Gao, Hai-Feng Sun, Li-Zeng Zhang, Guan-Hua Du, Xue-Mei Qin
OBJECTIVES: To investigate the antidepressant effects of Xiaoyaosan (XYS) in a chronic unpredictable mild stress (CUMS) depression model. METHODS: The changes in behaviour and plasma metabolic profiles were investigated after four-week CUMS exposure and treatment. Drugs were administered during the four-week period of CUMS, with the healthy group serving as negative controls, and the fluoxetine and venlafaxine groups serving as positive controls. Plasma samples were collected at 28th day, and the plasma metabolic profiling was measured using NMR, followed by multivariate analysis...
April 2012: Journal of Pharmacy and Pharmacology
Norio Watanabe, Ichiro M Omori, Atsuo Nakagawa, Andrea Cipriani, Corrado Barbui, Rachel Churchill, Toshi A Furukawa
BACKGROUND: Mirtazapine has a unique mechanism of antidepressive action and is one of the commonly used antidepressants in clinical practice. OBJECTIVES: The aim of the present review was to assess the evidence on the efficacy and acceptability of mirtazapine compared with other antidepressive agents in the acute-phase treatment of major depression in adults. SEARCH METHODS: We searched the Cochrane Collaboration Depression, Anxiety and Neurosis review group's specialised register (CCDANCTR), which includes relevant randomised controlled trials from the following bibliographic databases: The Cochrane Library (all years to April 2011), EMBASE, (1980 to July 2011) MEDLINE (1950 to July 2011) and PsycINFO (1974 to July 2011)...
2011: Cochrane Database of Systematic Reviews
Koen Demyttenaere
Long-term antidepressant treatment success should be viewed as the result of the cumulative effects of treatment at each stage of major depressive disorder (MDD), and as a balance between efficacy and tolerability/safety. Depression is a heterogeneous disorder and different mechanisms of action of different antidepressants probably capitalize on this response heterogeneity. Results from clinical trials with agomelatine, a melatonergic receptor agonist (MT(1)/MT(2)) and 5HT(2C) receptor antagonist, have shown that it is efficacious in both the acute phase and the continuation phase of treatment of depression...
September 2011: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
Adi Aran, Mali Einen, Ling Lin, Guiseppe Plazzi, Seiji Nishino, Emmanuel Mignot
STUDY OBJECTIVE: to report on symptoms and therapies used in childhood narcolepsy-cataplexy. DESIGN, PATIENTS, AND SETTING: retrospective series of 51 children who completed the Stanford Sleep Inventory. HLA-DQB1*0602 typing (all tested, and 100% positive), polysomnography or Multiple Sleep Latency Test (76%), and cerebrospinal fluid hypocretin-1 measurements (26%, all with low levels) were also conducted. Prospective data on medication response was collected in 78% using a specially designed questionnaire...
November 2010: Sleep
Sidney H Kennedy, Sakina J Rizvi
To demonstrate the clinical effectiveness of an antidepressant drug requires evidence beyond short- and long-term efficacy, including a favourable adverse-effect profile and sustained treatment adherence. Under these conditions, patients should experience enhanced social and functional outcomes. The novel antidepressant agomelatine, a melatonergic MT(1)/MT(2) receptor agonist with serotonin 5-HT(2C) receptor antagonist activity, displays antidepressant efficacy with a favourable adverse-effect profile that is associated with good patient adherence...
June 2010: CNS Drugs
Norio Watanabe, Ichiro M Omori, Atsuo Nakagawa, Andrea Cipriani, Corrado Barbui, Hugh McGuire, Rachel Churchill, Toshi A Furukawa
BACKGROUND: Mirtazapine has a unique mechanism of antidepressant action, and thus is thought to have a different profile of adverse events from that of other antidepressants. OBJECTIVE: To present a methodologically rigorous systematic review of the adverse event profile of mirtazapine and point to possible problems with safety reporting in randomized controlled trials (RCTs) of the acute-phase treatment of major depression in adults with mirtazapine in comparison with other types of antidepressant...
January 2010: CNS Drugs
N Sussman
An evolution in antidepressant development in recent decades has resulted in agents with selective mechanisms of action. Although agents with a single selective mechanism of action were initially thought to have advantages over other antidepressants, investigators now recognize that combined-action antidepressants, such as venlafaxine and clomipramine, may offer additional advantages in terms of increased efficacy and improved tolerability. In fact, a growing body of clinical evidence suggests that compared with the single-action selective serotonin reuptake inhibitors, both venlafaxine and once-daily venlafaxine extended release (venlafaxine XR) have shown an enhanced efficacy that extends over the entire spectrum of major depression and anxiety disorders, an earlier onset of action, less tendency to cause weight gain, and a low risk for potentially serious drug-drug interactions with many commonly used medications...
November 1999: Postgraduate Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"